FREQ [NASD]
Frequency Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own1.70% Shs Outstand34.81M Perf Week21.43%
Market Cap57.90M Forward P/E- EPS next Y-1.11 Insider Trans-4.28% Shs Float32.20M Perf Month30.77%
Income-87.70M PEG- EPS next Q-0.69 Inst Own46.20% Short Float5.49% Perf Quarter-30.45%
Sales9.40M P/S6.16 EPS this Y-199.90% Inst Trans-9.87% Short Ratio2.09 Perf Half Y-71.56%
Book/sh3.24 P/B0.47 EPS next Y47.10% ROA-45.40% Target Price8.67 Perf Year-84.65%
Cash/sh3.10 P/C0.49 EPS next 5Y- ROE-63.00% 52W Range1.00 - 10.34 Perf YTD-70.18%
Dividend- P/FCF- EPS past 5Y- ROI-57.60% 52W High-85.20% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low53.00% ATR0.15
Employees74 Current Ratio9.90 Sales Q/Q-100.00% Oper. Margin- RSI (14)61.78 Volatility16.55% 12.08%
OptionableYes Debt/Eq0.13 EPS Q/Q-12.50% Profit Margin- Rel Volume0.31 Prev Close1.51
ShortableYes LT Debt/Eq0.10 EarningsMay 04 AMC Payout- Avg Volume844.93K Price1.53
Recom2.40 SMA2026.08% SMA5018.77% SMA200-62.12% Volume262,476 Change1.32%
Sep-22-21Downgrade Goldman Buy → Neutral $12 → $9
Jan-27-21Upgrade JP Morgan Neutral → Overweight $56
Dec-22-20Initiated B. Riley Securities Buy $79
Jul-14-20Initiated Oppenheimer Outperform $36
May-18-20Downgrade JP Morgan Overweight → Neutral $27
Oct-28-19Initiated JP Morgan Overweight $25
Oct-28-19Initiated Goldman Buy $30
Oct-28-19Initiated Cowen Outperform
Jun-24-22 09:03AM  
May-25-22 12:00PM  
May-18-22 07:30AM  
May-04-22 04:30PM  
Apr-22-22 07:30AM  
Apr-08-22 05:00PM  
Mar-15-22 07:30AM  
Mar-10-22 06:35PM  
Feb-28-22 07:30AM  
Jan-14-22 05:43AM  
Jan-04-22 07:30AM  
Dec-28-21 02:38AM  
Dec-09-21 01:18PM  
07:30AM  
Nov-30-21 05:53AM  
Nov-15-21 12:25PM  
07:30AM  
Nov-09-21 07:30AM  
Nov-08-21 03:00PM  
Oct-27-21 07:30AM  
Oct-21-21 07:30AM  
Oct-01-21 08:23AM  
Sep-22-21 11:18AM  
07:30AM  
Sep-08-21 07:30AM  
Aug-30-21 05:10PM  
Aug-12-21 04:06PM  
08:45AM  
07:30AM  
Aug-04-21 03:00PM  
Aug-02-21 03:05PM  
02:30PM  
12:30PM  
12:30PM  
11:00AM  
10:00AM  
09:16AM  
09:09AM  
05:50AM  
03:27AM  
Aug-01-21 10:38AM  
06:36AM  
Jul-30-21 08:49PM  
07:19PM  
07:10PM  
05:15PM  
02:57PM  
01:30PM  
12:40PM  
11:30AM  
11:30AM  
11:00AM  
10:00AM  
10:00AM  
09:30AM  
09:00AM  
05:18AM  
Jul-29-21 08:47PM  
05:29PM  
04:02PM  
01:15PM  
12:30PM  
10:45AM  
10:00AM  
09:24AM  
05:27AM  
Jul-28-21 08:00PM  
07:25PM  
07:07PM  
05:34PM  
03:16PM  
01:45PM  
01:35PM  
01:15PM  
12:30PM  
11:00AM  
10:00AM  
09:33AM  
09:30AM  
09:07AM  
Jul-27-21 06:24PM  
05:32PM  
12:45PM  
11:15AM  
11:14AM  
10:40AM  
09:49AM  
09:00AM  
05:40AM  
12:50AM  
Jul-26-21 09:45PM  
08:10PM  
06:58PM  
05:28PM  
03:48PM  
03:23PM  
02:12PM  
01:55PM  
01:00PM  
12:10PM  
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Loose Christopher R.Chief Scientific OfficerFeb 22Sale3.531,0693,77434,827Feb 23 04:41 PM
LeBel CarlChief Development OfficerFeb 22Sale3.531,0693,77311,126Feb 23 04:36 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 22Sale3.531,5425,4428,927Feb 23 04:38 PM
McCubbin QuentinChief Manufacturing OfficerFeb 22Sale3.531,5845,59822,771Feb 23 04:34 PM
Arnold Wendy SChief People OfficerFeb 22Sale3.531,3264,68311,824Feb 23 04:32 PM
Arnold Wendy SChief People OfficerFeb 18Sale3.871,2094,68413,150Feb 23 04:32 PM
McCubbin QuentinChief Manufacturing OfficerFeb 18Sale3.871,4115,46324,355Feb 23 04:34 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 18Sale3.881,4045,44310,469Feb 23 04:38 PM
LeBel CarlChief Development OfficerFeb 18Sale3.879743,77212,195Feb 23 04:36 PM
Loose Christopher R.Chief Scientific OfficerFeb 18Sale3.879743,77235,896Feb 23 04:41 PM
Arnold Wendy SChief People OfficerFeb 17Sale4.191,1184,68814,359Feb 18 04:08 PM
LeBel CarlChief Development OfficerFeb 17Sale4.199013,77413,169Feb 18 04:12 PM
McCubbin QuentinChief Manufacturing OfficerFeb 17Sale4.201,3035,46725,766Feb 18 04:10 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 17Sale4.201,2965,44311,873Feb 18 04:14 PM
Loose Christopher R.Chief Scientific OfficerFeb 17Sale4.199003,77436,870Feb 18 04:13 PM
Loose Christopher R.Chief Scientific OfficerFeb 16Sale4.438513,76937,770Feb 18 04:13 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 16Sale4.431,2295,44313,169Feb 18 04:14 PM
McCubbin QuentinChief Manufacturing OfficerFeb 16Sale4.431,2335,46127,069Feb 18 04:10 PM
LeBel CarlChief Development OfficerFeb 16Sale4.438313,68014,070Feb 18 04:12 PM
Arnold Wendy SChief People OfficerFeb 16Sale4.431,0574,68115,477Feb 18 04:08 PM
LeBel CarlChief Development OfficerFeb 15Sale4.338443,65514,901Feb 16 05:05 PM
McCubbin QuentinChief Manufacturing OfficerFeb 15Sale4.331,2615,46128,302Feb 16 05:04 PM
Loose Christopher R.Chief Scientific OfficerFeb 15Sale4.338633,73838,621Feb 16 05:02 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 15Sale4.331,3475,83414,398Feb 16 04:59 PM
Arnold Wendy SChief People OfficerFeb 15Sale4.331,1685,05916,534Feb 16 04:50 PM
Lucchino David L.President and CEOJan 18Option Exercise0.616,9054,212470,111Jan 20 08:33 AM
Lucchino David L.President and CEODec 20Option Exercise0.616,9054,212463,206Dec 21 05:03 PM
Lucchino David L.President and CEONov 02Option Exercise0.616,9054,212456,301Nov 04 05:48 PM
Lucchino David L.President and CEOOct 05Option Exercise0.616,9054,212449,396Oct 07 04:13 PM
Lucchino David L.President and CEOSep 03Option Exercise0.616,9054,212442,491Sep 08 05:06 PM
Lucchino David L.President and CEOAug 03Option Exercise0.616,9054,212435,586Aug 05 05:08 PM
Lucchino David L.President and CEOJul 01Option Exercise0.616,9054,212428,681Jul 06 04:22 PM